ViiV Healthcare B.V.

ViiV Healthcare B.V. is a United Kingdom-based specialist pharmaceutical company dedicated to HIV prevention, treatment and long-term care. The business was created in 2009 by GSK and Pfizer by combining their HIV operations, with the purpose of giving HIV research and commercial activities a dedicated organizational focus rather than managing them as one therapeutic area within broader pharmaceutical portfolios. Japan's Shionogi later became a shareholder and contributed HIV assets and research capabilities to the company. GSK remains the controlling shareholder and provides much of the corporate infrastructure behind ViiV. The company operates across the HIV medicines lifecycle, including discovery research, clinical development, regulatory submissions, manufacturing, access programs and commercial distribution. Its portfolio covers several treatment classes, including nucleoside and nucleotide reverse-transcriptase inhibitors, integrase inhibitors, entry and attachment inhibitors, and long-acting injectable therapies. Major products associated with ViiV include dolutegravir brands such as Tivicay, combination products such as Triumeq and Dovato, the two-drug regimen Juluca, the long-acting cabotegravir products Vocabria and Apretude, the fixed-dose injectable HIV treatment Cabenuva developed with Janssen, and earlier products including Ziagen and Epivir. Portfolio availability and marketing authorization vary by country. ViiV's principal strategic distinction is its single-disease focus. Rather than competing as a general pharmaceutical company, it positions itself as a dedicated HIV specialist with capabilities spanning prevention, first-line and treatment-experienced patient care, pediatric treatment, adherence support and public-health access. The company has emphasized simplified regimens, durable viral suppression, reduced pill burden and long-acting administration. Its cabotegravir-based products have extended the business beyond daily oral treatment into HIV prevention and injectable treatment, while its dolutegravir franchise has been central to global HIV treatment programs. The company also conducts research into new mechanisms and formulations, including long-acting medicines, and works with public-health organizations, governments, generic manufacturers and community groups to expand access. ViiV has used voluntary licensing and access-oriented commercial arrangements for selected medicines, particularly in lower-income countries, although the affordability and availability of HIV medicines remain subjects of continuing public debate. Its Positive Action program supports community and civil-society organizations working on HIV-related stigma, prevention, testing, treatment literacy and social inclusion. ViiV is not a separately listed public company and does not have its own stock-market ticker. It is a corporate subsidiary and joint-venture-style operating company within the GSK group. The legal name supplied for this record is ViiV Healthcare B.V.; public-facing materials generally use the shorter name ViiV Healthcare. The company remains active and is one of the most prominent specialist HIV pharmaceutical organizations in the global market.

ViiV Healthcare was established in 2009 when GSK and Pfizer combined their HIV research and commercial operations. The venture was designed as a focused HIV company at a time when the disease area was becoming increasingly specialized, with treatment requiring long-term combination therapy, resistance management, adherence support and close attention to public-health delivery. Its creation brought together GSK's established HIV portfolio and Pfizer's HIV assets, including the CCR5 antagonist maraviroc. From its beginning, ViiV was structured as a dedicated operating company rather than a conventional independent pharmaceutical corporation. GSK became the controlling shareholder, Pfizer retained a minority interest, and the company used the combined research, development, manufacturing and commercial resources of its parents. Shionogi later joined the ownership structure and contributed intellectual property and development collaboration related to dolutegravir, an integrase inhibitor that became one of the central medicines in modern HIV treatment. The early portfolio included established medicines such as Ziagen, Epivir, Combivir and Kivexa, as well as newer products and pipeline candidates. The principal strategic breakthrough was the development and commercialization of dolutegravir. Marketed as Tivicay and incorporated into fixed-dose combinations including Triumeq and Dovato, dolutegravir became important because of its strong antiviral activity, high barrier to resistance and suitability for simplified regimens. ViiV subsequently broadened the treatment portfolio with Juluca, a two-drug regimen pairing dolutegravir with rilpivirine, and with products intended for people with multidrug-resistant HIV, such as Rukobia. A second major phase began with the development of long-acting cabotegravir. ViiV's injectable technology was used in partnership with Janssen to create Cabenuva, a long-acting complete treatment regimen combining cabotegravir and rilpivirine. The company also developed cabotegravir as a prevention medicine. Its approval as Apretude provided an HIV pre-exposure prophylaxis option administered at intervals rather than taken as a daily oral tablet. These products changed ViiV's role from an established oral-treatment supplier into a significant participant in long-acting HIV treatment and prevention. Access has remained a prominent part of ViiV's identity. The company has used voluntary licensing, tiered pricing, supply agreements and partnerships with governments and international organizations for selected HIV medicines. It has also supported community organizations through Positive Action, a program addressing stigma, prevention, testing, treatment literacy and the social factors that affect HIV outcomes. Such activities reflect the unusual position of HIV pharmaceutical companies, whose commercial decisions are closely connected with global public-health policy. The company has faced the same debates that affect the wider HIV industry, including questions about patent duration, pricing, generic competition and the speed at which new medicines reach lower-income countries. ViiV's response has generally combined protection of intellectual property in commercial markets with licensing and access mechanisms for specified countries and patient populations. Availability, reimbursement and regulatory status remain different across jurisdictions. ViiV continues to operate as an active GSK-controlled specialist company. Its business is centered on HIV research, branded medicines, prevention and long-acting delivery, while its partnerships extend the reach of its products beyond the markets in which it directly commercializes them. The supplied legal-name form, ViiV Healthcare B.V., refers to a corporate entity within this wider operating structure; the public brand is normally written as ViiV Healthcare.

• 2021

  Cabenuva and Apretude launch in the United States

  [5]U.S. Food and Drug Administration: Apretude approvalfda.gov

  Long-acting cabotegravir becomes available in the United States both as part of injectable HIV treatment and as the prevention product Apretude.

• 2019

  Dovato receives regulatory approval

  [10]Dovato receives regulatory approvalfda.gov

  Dovato, a two-drug dolutegravir and lamivudine regimen, is approved in the United States for adults with HIV-1 without prior antiretroviral treatment.

• 2017

  Deborah Waterhouse becomes chief executive

  [2]ViiV Healthcare: Leadershipviivhealthcare.com

  Deborah Waterhouse succeeds as ViiV Healthcare's chief executive, leading the company through expansion of its treatment and long-acting pipeline.

• 2014

  Triumeq is approved

  [9]Triumeq is approvedfda.gov

  The FDA approves Triumeq, a once-daily fixed-dose combination containing dolutegravir, abacavir and lamivudine.

• 2013

  Tivicay receives United States approval

  [7]U.S. Food and Drug Administration: Tivicay approvalfda.gov

  The FDA approves dolutegravir as Tivicay for use with other antiretroviral agents in the treatment of HIV-1 infection.

• 2012

  Dolutegravir partnership advances

  [8]Dolutegravir partnership advancesviivhealthcare.com

  ViiV and Shionogi advance development of dolutegravir, an integrase inhibitor that later becomes a core ViiV franchise.

• 2009

  ViiV Healthcare is established

  [1]ViiV Healthcare: About usviivhealthcare.com

  GSK and Pfizer combine their HIV businesses to create a dedicated specialist company.

A global, specialist HIV company focused on innovative oral and long-acting medicines, HIV prevention, treatment simplification and access-oriented public-health partnerships.

• HIV integrase inhibitor · 2013

  Tivicay

  Tivicay is the brand name for dolutegravir, an integrase strand transfer inhibitor used with other antiretroviral medicines to treat HIV-1 infection. It became a foundation of ViiV's modern portfolio because of its potency, once-daily use in many treatment settings and high barrier to resistance. Authorization details and approved patient populations differ by market.

• Fixed-dose HIV treatment combination · 2014

  Triumeq

  Triumeq combines dolutegravir, abacavir and lamivudine in a single-tablet regimen. It was designed to reduce pill burden while retaining a three-drug treatment approach. The product is subject to patient-selection requirements, including consideration of abacavir-associated hypersensitivity risk and relevant genetic testing in markets where such testing is recommended.

• Two-drug HIV treatment combination · 2019

  Dovato

  Dovato is a once-daily fixed-dose combination of dolutegravir and lamivudine. It represents ViiV's treatment-simplification strategy by providing a complete two-drug regimen for eligible adults. Its use depends on regulatory labeling, viral-resistance history and clinical circumstances.

• Two-drug HIV treatment combination · 2017

  Juluca

  Juluca combines dolutegravir with rilpivirine as a complete two-drug regimen for adults whose HIV is already virologically suppressed and who meet the relevant treatment criteria. It is part of ViiV's effort to offer durable viral suppression with fewer active medicines in an appropriately selected population.

• Long-acting injectable HIV treatment · 2021

  Cabenuva

  Cabenuva is a long-acting injectable complete HIV treatment regimen based on cabotegravir from ViiV and rilpivirine from Janssen. It is administered by healthcare professionals at scheduled intervals after assessment of treatment suitability. The product was a major step away from daily oral therapy for appropriately selected adults.

• HIV pre-exposure prophylaxis · 2021

  Apretude

  Apretude is an extended-interval injectable formulation of cabotegravir used for pre-exposure prophylaxis to reduce the risk of sexually acquired HIV. It is intended for people at risk of HIV and requires an initiation and continuing injection schedule, together with HIV testing and clinical follow-up.

• Oral cabotegravir and long-acting treatment support · 2021

  Vocabria

  Vocabria contains cabotegravir and is used in association with long-acting rilpivirine for the treatment of HIV in eligible adults. Depending on the jurisdiction and regimen, oral cabotegravir can support initiation or provide oral coverage around injections. It forms part of ViiV's long-acting treatment platform.

• HIV attachment inhibitor · 2020

  Rukobia

  Rukobia is the brand name for fostemsavir, an attachment inhibitor used with other antiretroviral medicines in heavily treatment-experienced adults with multidrug-resistant HIV-1 whose current regimen cannot otherwise provide a complete suppressive regimen. It addresses a specialized treatment population with limited remaining options.

• Nucleoside reverse-transcriptase inhibitor · 1999

  Ziagen

  Ziagen contains abacavir, a nucleoside reverse-transcriptase inhibitor used in combination with other antiretroviral medicines. It is also a component of combination products such as Triumeq. Its use requires attention to the risk of abacavir hypersensitivity and applicable genetic screening recommendations.

• Nucleoside reverse-transcriptase inhibitor · 1995

  Epivir

  Epivir is the brand name for lamivudine, an established nucleoside reverse-transcriptase inhibitor used in HIV combination therapy. Lamivudine is also included in several fixed-dose combinations and has been important in expanding simple, broadly deployable antiretroviral regimens.

• 1992Positive Action

  Global

  Positive Action is ViiV's long-running community and social-impact program supporting organizations addressing HIV prevention, stigma, testing, treatment access, adherence and the wider social conditions affecting people living with HIV.

  Outcome. The program has provided grants and partnerships to community and civil-society organizations in multiple regions. Specific annual results vary by program and are reported separately.

  Source

• 2018

  Move toward long-acting HIV treatment and preventionGeneration change

  Background

  Daily oral treatment remains effective but can be difficult for some patients because of adherence, stigma, privacy and treatment fatigue.

  Action taken

  ViiV invested in long-acting cabotegravir development for both treatment and pre-exposure prophylaxis, including collaboration with Janssen for Cabenuva.

  Aftermath

  The resulting approvals created an injectable treatment and prevention franchise and broadened ViiV's role in HIV care beyond oral medicines.

  Source

• 2012

  Expansion of the dolutegravir platformStrategy

  Background

  The company sought to strengthen its HIV portfolio with an integrase inhibitor that could support both standalone and fixed-dose combination products.

  Action taken

  ViiV and Shionogi advanced dolutegravir development, leading to the Tivicay brand and later combination regimens.

  Aftermath

  Dolutegravir became one of ViiV's most important treatment platforms and supported the company's expansion in first-line and simplified HIV therapy.

  Source

• 2009

  Creation of a dedicated HIV companyM&A

  Background

  GSK and Pfizer held substantial HIV portfolios but chose to combine their operations into a specialist company focused on one disease area.

  Action taken

  The companies formed ViiV Healthcare, with GSK as controlling shareholder and Pfizer retaining a minority interest.

  Aftermath

  ViiV became a dedicated platform for HIV research, development, access programs and commercialization rather than a conventional broad-therapy pharmaceutical division.

  Source

• 2020.07.03

  Reported2020.07.03

  FDA approves ViiV Healthcare's Rukobia[13]FDA批准ViiV Healthcare的Rukobiapharmatimes.com

  The US Food and Drug Administration approved ViiV Healthcare's Rukobia (fostemsavir) for use with other antiretroviral therapies in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection.

• Unconfirmed

  Reported2020.06.16

  FDA approves pediatric Tivicay PD tablet[14]FDA批准儿童用 Tivicay PD 锭剂poz.com

  The FDA approved ViiV Healthcare’s Tivicay PD dispersible tablet, in combination with other antiretrovirals, for HIV treatment in children at least 4 weeks old who weigh at least 6 pounds 10 ounces.

• 2020.04.28

  Reported2020.04.28

  ViiV Healthcare establishes £3 million COVID-19 response fund[15]ViiV Healthcare设立300万英镑新冠疫情应对基金pharmatimes.com

  ViiV Healthcare established a £3 million fund to support research into COVID-19's medical and scientific impact on people living with HIV and community-based activities addressing challenges they face. The fund was divided equally between research and community response programmes, each receiving up to £1.5 million.

• 2019.11.21

  Reported2019.11.21

  ViiV Healthcare announces exclusive N6LS licensing agreement with NIAID[16]ViiV Healthcare宣布与NIAID达成N6LS独家许可协议gsk.com

  ViiV Healthcare announced that it will develop investigational antibody N6LS for HIV treatment and prevention under an exclusive licensing agreement between GSK and NIAID, part of the National Institutes of Health. The announcement describes development plans, not a completed treatment launch.

Read more

1. 1ViiV Healthcare: About usviivhealthcare.com
2. 2ViiV Healthcare: Leadershipviivhealthcare.com
3. 3ViiV Healthcare: Our medicinesviivhealthcare.com
4. 4ViiV Healthcare: HIV community accessviivhealthcare.com
5. 5U.S. Food and Drug Administration: Apretude approvalfda.gov
6. 6U.S. Food and Drug Administration: Cabenuva approvalfda.gov
7. 7U.S. Food and Drug Administration: Tivicay approvalfda.gov
8. 8Dolutegravir partnership advancesviivhealthcare.com
9. 9Triumeq is approvedfda.gov
10. 10Dovato receives regulatory approvalfda.gov
11. 11Positive Actionviivhealthcare.com
12. 12Move toward long-acting HIV treatment and preventionviivhealthcare.com
13. 13FDA批准ViiV Healthcare的Rukobiapharmatimes.com
14. 14FDA批准儿童用 Tivicay PD 锭剂poz.com
15. 15ViiV Healthcare设立300万英镑新冠疫情应对基金pharmatimes.com
16. 16ViiV Healthcare宣布与NIAID达成N6LS独家许可协议gsk.com